CNBC today published an article wherein the founder of Vanguard Group discussed his view on the necessity of investing in equities, which while higher risk, offer the potential for higher reward.
/apple-app-store.png?width=97&name=apple-app-store.png)
/google-play.png?width=88&name=google-play.png)
Posted by Laura Swartz
August 6, 2012 at 5:04 PM
CNBC today published an article wherein the founder of Vanguard Group discussed his view on the necessity of investing in equities, which while higher risk, offer the potential for higher reward.
Topics: Crystal Research Associates, T3 Motion, Advaxis, Bioniche, Pluristem Therapeutics, Peregrine, Adamis
Posted by Karen Goldfarb
January 13, 2012 at 11:20 AM
This has been a big week for healthcare and biotech.
Topics: Crystal Research Associates, NVIV, GenSpera, OneMedForum, MedPro, biotech, Advaxis, Peregrine, Neuralstem, Leslie Ziegler, Gunnar Weikert, PPHM, General Cannabis, SearchCore
Last week, several companies within our coverage universe released financial results and corporate updates, including CEL-SCI Corporation (CVM-NYSE Amex), Pro-Pharmaceuticals Inc. (PRWP-OTC), and Advaxis Inc. (ADXS-OTC). In addition, Neuralstem, Inc. (CUR?-NYSE Amex)? announced a breakthrough in its clinical trials that it believes could greatly influence the treatment of amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease—a potentially fatal neuromuscular disorder.
Topics: Newsworthy Events, Advaxis, CEL-SCI, Multikine
Posted by Laura Swartz
November 15, 2010 at 10:33 AM
As part of the Patient Protection and Affordable Care Act of 2010, Congress established a program known as the Qualifying Therapeutic Discovery Project (QTDP) to offer tax credits or grants for projects that show significant potential to produce new and cost-saving therapies, support jobs, and increase the U.S.’s competitiveness. Under the program, a total of $1 billion is allocated for credits and grants.
Topics: Newsworthy Events, Advaxis
We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.
CONTACT INFORMATION
Phone: (212) 851-6685
/facebook.png)
FACEBOOK/twitter.png)
TWITTER/youtube.png)
YOUTUBE/linkedin.png)
LINKEDIN/slideshare.png)
SLIDESHARE/rss.png)
RSS